Citations

Clear

511 citation(s) found for "Seth, N".

Quantifying Individual-Level Uncertainty in GFR Estimation
Zhu, Xiaoqian , Mosley, Tom, Butler, Javed , Hall, Michael E. , Vaitla, Pradeep , Lirette, Seth T. , Rule, Andrew D. , Butler, Kenneth R. , Wynn, James J., Dossabhoy, Neville R. , Güallar, Eliseo , Shafi, Tariq

Mayo Clinic

Journal of the American Society of Nephrology | May 17, 2024 | Volume: 32 | Issue: 10S | Pages: 19-19

10.1681/asn.20213210s119a Get It

Characteristics of emerging new autoimmune diseases after COVID‐19 vaccination: A sub‐study by the COVAD group
Shumnalieva, Russka , Ravichandran, Naveen , Javaid, Mahnoor , Darooka, Naitica , Gonzalez, Daniel E., Velikova, Tsvetelina , Milchert, Marcin , Kuwana, Masataka , Boyd, Peter , Yaadav, Praggya , Cheng, Karen Kow Yip , Kobert, Linda , Gutiérrez, Carlos Enrique Toro , Caballero‐Uribe, Carlo V. , Parodis, Ioannis , Dey, Dzifa , Nikiphorou, Elena , Kadam, Esha , Tan, Ai Lyn , Chinoy, Hector , Gupta, Latika, Group, COVAD Study, Agarwal, Vikas , Tehozol, Erick Adrian Zamora , Gupta, Latika , Javaid, Mahnoor , Darooka, Naitica , Velikova, Tsvetelina , Milchert, Marcin , Kuwana, Masataka , Joshi, Mrudula , Gracia-Ramos, Abraham Edgar , Boyd, Peter , Yaadav, Praggya , Cheng, Karen , Cavagna, Lorenzo , Sen, Parikshit , Day, Jessica , Makol, Ashima , Gutiérrez, Carlos Enrique Toro , Caballero-Uribe, Carlo Vinicio , Saha, Sreoshy , Parodis, Ioannis , Dey, Dzifa , Nikiphorou, Elena , Distler, Oliver , Kadam, Esha , Tan, Ai Lyn , Shinjo, Samuel Katsuyuki , Ziade, Nelly , Knitza, Johannes , Chinoy, Hector , Aggarwal, Rohit , Agarwal, Vikas , Gupta, Latika , Agarwal, Vikas , Naveen, R , Zamora Tehozol, Erick Adrian , Shumnalieva, Russka , Hannah, Jennifer R. , Roy, Debaditya , Joshi, Mrudula , Gracia‐Ramos, Abraham Edgar , Sen, Parikshit , Day, Jessica , Makol, Ashima , Saha, Sreoshy , Distler, Oliver , Shinjo, Samuel Katsuyuki , Ziadé, Nelly , Aggarwal, Rohit , Group, COVAD Study

Mayo Clinic

International Journal of Rheumatic Diseases | May 14, 2024 | Volume: 27 | Issue: 5 | Pages: No page available

10.1111/1756-185x.15178 | PMID 38742751 Get It

AbstractBackgroundDespite the overall safety and efficacy of COVID‐19 vaccinations, rare cases of systemic autoimmune diseases (SAIDs) have been reported post‐vaccination. This study used a global survey to analyze SAIDs in susceptible individuals' post‐vaccination.MethodsA cross‐sectional study was conducted among participants with self‐reported new‐onset SAIDs using the COVID‐19 Vaccination in Autoimmune Diseases (COVAD) 2 study dataset—a validated, patient‐reported e‐survey—to analyze the long‐term safety of COVID‐19 vaccines. Baseline characteristics of patients with new‐onset SAIDs and vaccinated healthy controls (HCs) were compared after propensity score matching based on age and sex in a 1:4 ratio.ResultsOf 16 750 individuals, 74 (median age 52 years, 79.9% females, and 76.7% Caucasians) had new‐onset SAID post‐vaccination, mainly idiopathic inflammatory myopathies (IIMs) (n = 23, 31.51%), arthritis (n = 15; 20.53%), and polymyalgia rheumatica (PMR) (n = 12, 16.40%). Higher odds of new‐onset SAIDs were noted among Caucasians (OR = 5.3; 95% CI = 2.9–9.7; p < .001) and Moderna vaccine recipients (OR = 2.7; 95% CI = 1.3–5.3; p = .004). New‐onset SAIDs were associated with AID multimorbidity (OR = 1.4; 95% CI = 1.1–1.7; p < .001), mental health disorders (OR = 1.6; 95% CI = 1.3–1.9; p < .001), and mixed race (OR = 2.2; 95% CI = 1.2–4.2; p = .010), where those aged >60 years (OR = 0.6; 95% CI = 0.4–0.8; p = .007) and from high/medium human development index (HDI) countries (compared to very high HDI) reported fewer events than HCs.ConclusionThis study reports a low occurrence of new‐onset SAIDs following COVID‐19 vaccination, primarily IIMs, PMR, and inflammatory arthritis. Identified risk factors included pre‐existing AID multimorbidity, mental health diseases, and mixed race. Revaccination was well tolerated by most patients; therefore, we recommend continuing COVID‐19 vaccination in the general population. However, long‐term studies are needed to understand the autoimmune phenomena arising post‐vaccination.
Listening to patients, for the patients: The COVAD Study—Vision, organizational structure, and challenges
Joshi, Mrudula , Darooka, Naitica , Saha, Sreoshy , Dyball, Sarah , Sen, Parikshit , Yaadav, Praggya , Javaid, Mahnoor , Kadam, Esha , Shinjo, Samuel Katsuyuki , Dey, Dzifa , Gutiérrez, Carlos Enrique Toro , Caballero‐Uribe, Carlo V. , Kuwana, Masataka , Burmester, Gerd R , Ziadé, Nelly , Wincup, Chris , Parodis, Ioannis , Tan, Ai Lyn , Wang, Guochun , Dalbeth, Nicola , Velikova, Tsvetelina , Nikiphorou, Elena , Agarwal, Vikas , Gupta, Latika, group, the COVAD study, Tehozol, Erick Adrian Zamora , Alpizar-Rodriguez, D. , Singla, Shikha , Cheng, Karen Kow Yip , Gupta, Latika , Cavagna, Lorenzo , Makol, Ashima , Gutiérrez, Carlos Enrique Toro , Caballero-Uribe, Carlo Vinicio , Kuwana, Masataka , Burmester, Gerd-Rüdiger , Ziade, Nelly , Wincup, Chris , Andreoli, Laura , Parodis, Ioannis , Tan, Ai Lyn , Guillemin, Francis , Knitza, Johannes , Wang, Guochun , Dalbeth, Nicola , Velikova, Tsvetelina , Gracia-Ramos, Abraham Edgar , Nikiphorou, Elena , Day, Jessica , Chinoy, Hector , Aggarwal, Rohit , Agarwal, Vikas , Gupta, Latika , Joshi, Mrudula , Shinjo, Samuel Katsuyuki , Alpízar-Rodríguez, Deshiré , Zamora Tehozol, Erick Adrian , Dey, Dzifa , Sen, Parikshit , Saha, Sreoshy , Darooka, Naitica , Yaadav, Praggya , Cheng, Karen , Kadam, Esha , Makol, Ashima , Andréoli, Laura , Gracia‐Ramos, Abraham Edgar , Day, Jessica , Chinoy, Hector , Aggarwal, Rohit , group, the COVAD study

Mayo Clinic

International Journal of Rheumatic Diseases | May 9, 2024 | Volume: 27 | Issue: 5 | Pages: No page available

10.1111/1756-185x.15161 | PMID 38720408 Get It

AbstractBackgroundThe pandemic presented unique challenges for individuals with autoimmune and rheumatic diseases (AIRDs) due to their underlying condition, the effects of immunosuppressive treatments, and increased vaccine hesitancy.ObjectivesThe COVID‐19 vaccination in autoimmune diseases (COVAD) study, a series of ongoing, patient self‐reported surveys were conceived with the vision of being a unique tool to gather patient perspectives on AIRDs. It involved a multinational, multicenter collaborative effort amidst a global lockdown.MethodsLeveraging social media as a research tool, COVAD collected data using validated patient‐reported outcomes (PROs). The study, comprising a core team, steering committee, and global collaborators, facilitated data collection and analysis. A pilot‐tested, validated survey, featuring questions regarding COVID‐19 infection, vaccination and outcomes, patient demographics, and PROs was circulated to patients with AIRDs and healthy controls (HCs).DiscussionWe present the challenges encountered during this international collaborative project, including coordination, data management, funding constraints, language barriers, and authorship concerns, while highlighting the measures taken to address them.ConclusionCollaborative virtual models offer a dynamic new frontier in medical research and are vital to studying rare diseases. The COVAD study demonstrates the potential of online platforms for conducting large‐scale, patient‐focused research and underscores the importance of integrating patient perspective into clinical care. Care of patients is our central motivation, and it is essential to recognize their voices as equal stakeholders and valued partners in the study of the conditions that affect them.
Abstract PO2-14-09: Baseline genomic alterations and the activity of lasofoxifene (LAS) plus abemaciclib (Abema) in patients with ER+/HER2- metastatic breast cancer (mBC): the ELAINE 2 study
O’Sullivan, Ciara C. , Riordan, Gary, Rugo, Hope, Carroll, Dominic, Plourde, Paul V., Portman, David, Yam, Einav Nili-Gal, Damodaran, Senthil , Cristofanilli, Massimo , Goetz, Matthew P. , Stover, Daniel G. , Wander, Seth Andrew

Mayo Clinic

Cancer Research | May 2, 2024 | Volume: 84 | Issue: 9_Supplement | Pages: PO2-14-09-PO2-14-09

10.1158/1538-7445.sabcs23-po2-14-09 Get It

Abstract Introduction: Estrogen receptor-positive (ER+)/HER2-negative (HER2-) breast cancers commonly acquire constitutively active mutations in the ERα-encoding gene (ESR1), resulting in endocrine therapy (ET) resistance. In the phase 2, ELAINE 2 study (NCT04432454), LAS (a breast ER antagonist) combined with Abema provided a median progression-free survival (PFS) of ~13 months (mos) and clinical benefit rate (CBR) of 66% in patients with endocrine-resistant, ER+/HER2- mBC and ESR1 mutations (mESR1; Damodaran. J Clin Oncol 2023;41:suppl16;1057). Our objective was to describe baseline genomic alterations co-occuring with mESR1 and treatment responses to LAS plus Abema in patients with these concurrent genomic alterations. Methods: Women (age ≥18 yrs) with ER+/HER2- mBC that progressed after prior ET and CDK4/6 inhibitor (CDK4/6i) with an mESR1 detected in blood using the Sysmex-Inostics SafeSeq circulating tumor DNA (ctDNA) test were enrolled in ELAINE 2. Oral LAS 5 mg/day and Abema (provided by Eli Lilly and Co) 150 mg BID were taken until disease progression, death, unacceptable toxicity, or withdrawal. The Guardant360 CDx test was used to identify and describe baseline genomic alterations in ctDNA (including mESR1). Median PFS and CBR were assessed in patients with mESR1 and co-existing baseline genomic alterations. For patients who withdrew before disease progression, their last observation time was used as the progression time for PFS estimation. Data were summarized descriptively with no formal hypothesis testing. Results: Of the 29 patients (median age 60 yrs) enrolled, mutations in ESR1 were identified in 26 by Guardant360; all these 26 patients had received prior CDK4/6i, 21 (81%) prior fulvestrant, and 12 (46%) prior chemotherapy for mBC. Alterations in 39 genes were concurrently identified with mESR1, including TP53 mutations (n=11), PIK3CA mutations (n=8), CCND1 amplifications (n=6), and FGFR1 amplifications (n=5); co-amplification of CCND1 and FGFR1 was identified in 3 patients. LAS plus Abema treatment was associated with a CBR of 73% and a median PFS of 12.9 mos in the 26 patients with mESR1 (Table). CBRs were 63% in the co-occurring PIK3CA mutation subgroup and 64% in the TP53 mutation subgroup; median PFS times were 7.8 and 8.3 mos, respectively. All patients in the CCND1 and FGFR1 amplification subgroups achieved clinical benefit (CBR 100%) and the median PFS was 16.6 mos for both subgroups. In patients with mESR1 and co-alterations in ≥2 other genes of interest (PIK3CA, FGFR1, CCND1, TP53, ERBB2, CCNE1, or RB1), CBR was 83% and median PFS was 16.6 mos. Conclusion: Using Guardant360 ctDNA profiling from patients in ELAINE 2, we demonstrate that other baseline genomic alterations are frequently detected concurrently with mESR1 in the endocrine resistant setting, but without apparent compromise on the efficacy of LAS plus Abema. These results should be interpreted with caution considering the small numbers of patients and the exploratory nature of the analysis. The ELAINE 2 study suggests the potential of LAS plus Abema for treating ESR1-mutated, ER+/HER2- mBC in the post-CDK4/6i setting. This will be further evaluated in the larger, registrational, phase 3, ELAINE 3 study (NCT05696626) that compares LAS plus Abema with fulvestrant plus Abema. Table. Treatment response by genomic alterations concurrent with ESR1 mutations (n=26). aFor patients who withdrew before disease progression, the last observation time was used as the progression time for PFS estimation. bOther genes of interest include PIK3CA, FGFR1, CCND1, TP53, ERBB2, CCNE1, or RB1. CBR, clinical benefit rate; mPFS, median progression-free survival. Citation Format: Senthil Damodaran, Massimo Cristofanilli, Matthew Goetz, Ciara O'Sullivan, Gary Riordan, Hope Rugo, Daniel Stover, Seth Wander, Dominic Carroll, Paul V. Plourde, David J Portman, Einav Nili-Gal Yam. Baseline genomic alterations and the activity of lasofoxifene (LAS) plus abemaciclib (Abema) in patients with ER+/HER2- metastatic breast cancer (mBC): the ELAINE 2 study [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO2-14-09.
Abstract PO1-18-12: Trial in progress: Open-label, randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating locally advanced or ER+/HER2- metastatic breast cancer with an ESR1 mutation
Batist, Gerald , Cortés, Javier, Yam, Einav Nili-Gal, Cynthia, X. , Parsons, Heather A. , Sammons, Sarah , Twelves, Chris, Bardia, Aditya , Plourde, Paul V., Portman, David, Sammons, Sarah L , Goetz, Matthew P. , Wander, Seth Andrew , Bachelot, Thomas , Cortés, Javier , Cristofanilli, Massimo , Curigliano, Giuseppe , Nonneville, Alexandre Tassin de , Jhaveri, Komal , Rugo, Hope S. , Stover, Daniel G. , Damodaran, Senthil

Mayo Clinic

Cancer Research | May 2, 2024 | Volume: 84 | Issue: 9_Supplement | Pages: PO1-18-12-PO1-18-12

10.1158/1538-7445.sabcs23-po1-18-12 Get It

Abstract Background: Patients with estrogen receptor-positive (ER+) metastatic breast cancer (BC) may develop resistance to endocrine therapy (ET), particularly following treatment with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i), potentially driven by a mutation in the ERa-coding gene, ESR1. Lasofoxifene, an oral, next-generation ET and ER breast antagonist, had potent activity in mBC xenograft models expressing ESR1 mutations, either as a single agent or combined with a CDK4/6i. Subsequently, two phase 2 studies evaluated lasofoxifene in women with ER+/HER2- metastatic BC and an ESR1 mutation who had disease progression on previous ET and CDK4/6i. The ELAINE 1 trial showed numerically greater progression-free survival (PFS, median ~6 vs 4 months; P=0.138), objective response rate (ORR, 13% vs 3%; P=0.124), and clinical benefit rate (CBR, 37% vs 22%; P=0.117) with lasofoxifene monotherapy versus the ER degrader fulvestrant, with a favorable safety profile (Goetz MP, et al. Ann Oncol. 2022;33:S1387). The single-arm, ELAINE 2 trial demonstrated that lasofoxifene combined with abemaciclib was well tolerated with a median PFS of ~13 months, ORR of 56%, and CBR of 66% (Damodaran S, et al. J Clin Oncol. 2023;41:suppl 16; abstr 1057). Based on these data, the phase 3, registrational, ELAINE 3 trial was initiated. Methods: ELAINE 3 (NCT05696626) is an open-label, phase 3, multicenter study evaluating the efficacy, safety, and tolerability of lasofoxifene plus abemaciclib versus fulvestrant plus abemaciclib. Key inclusion criteria are pre- and postmenopausal women and men aged ≥18 years; ER+/HER2-, locally advanced and/or metastatic BC (measurable and/or non-measurable disease); ≥1 acquired ESR1 mutation; progression on an aromatase inhibitor plus palbociclib or ribociclib as their first hormonal treatment for advanced/metastatic BC; and ≤1 line of chemotherapy in the advanced/metastatic setting. Patients will be randomized 1:1 to receive lasofoxifene 5 mg/day plus abemaciclib 150 mg BID, or fulvestrant 500 mg IM on days 1, 15, and 29, then 4 weekly plus abemaciclib 150 mg BID. Treatment will continue until progression, death, unacceptable toxicity, or withdrawal from the study. The primary endpoint is PFS; key secondary endpoints are ORR, overall survival, CBR, duration of response, and time to response. Time to cytotoxic chemotherapy, quality of life, and safety will also be evaluated. Blood samples for circulating tumor DNA (ctDNA) will be collected at screening, at weeks 4 and 8 and every 8 weeks thereafter, and at the final visit for genomic analyses. Outcomes with lasofoxifene/abemaciclib and fulvestrant/abemaciclib will be compared using a stratified Cox proportional hazards model and stratified logrank test. Expected PFS is ≥10.3 months for lasofoxifene/abemaciclib and 7 months for fulvestrant/abemaciclib (PFS hazard ratio of 0.68 at final analysis). The target sample size is 400, to achieve 90% power with a one-sided type I error rate of 0.025 after 285 PFS events. Full recruitment is expected to occur over 18 months at 125 global sites. Citation Format: Matthew Goetz, Seth Wander, Thomas Bachelot, Gerald Batist, Javier Cortés, Massimo Cristofanilli, Giuseppe Curigliano, Alexandre de Nonneville, Einav Nili-Gal Yam, Komal Jhaveri, Cynthia Ma, Heather Parsons, Hope Rugo, Sarah Sammons, Daniel Stover, Chris Twelves, Aditya Bardia, Paul V. Plourde, David J Portman, Senthil Damodaran. Trial in progress: Open-label, randomized, multicenter, phase 3, ELAINE 3 study of the efficacy and safety of lasofoxifene plus abemaciclib for treating locally advanced or ER+/HER2- metastatic breast cancer with an ESR1 mutation [abstract]. In: Proceedings of the 2023 San Antonio Breast Cancer Symposium; 2023 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2024;84(9 Suppl):Abstract nr PO1-18-12.
Airway Mucus Plugging and Cause-specific Mortality in COPD
Mettler, S.K., Nath, P. H., Yen, A.A., Kligerman, Seth , Jacobs, Kathleen, Manapragada, Padma P. , Abozeed, Mostafa , Zahid, Mohd , Ahmed, Asmaa , Terry, Nina , Elalami, Rim, Sonavane, Sushilkumar K. , Billatos, Ehab , Wang, Wei , Cho, M.H. , Grumley, Scott , Kim, Katherine Callaway , Nardelli, Pietro , Aziz, Muhammad Usman , Estépar, Raúl San Jośe , Abdalla, M., Díaz, Alejandro A.

Mayo Clinic

C24. CLINICAL, BIOLOGIC, AND RADIOLOGIC MARKERS OF KEY OUTCOMES AND TREATMENT RESPONSE IN COPD | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A5122-A5122

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a5122 Get It

Association Between Adjunctive Vasopressors and Short-term Mortality in Adults With Septic Shock: A Systematic Review and Meta-analysis
Turpin, Brittany D. Bissell, Falck–Ytter, Yngve , Bauer, Seth R , Wieruszewski, Patrick M. , Dugar, Siddharth , Sacha, Gretchen , Sato, Ryota , Siuba, Matthew , Schleicher, Mary , Vachharajani, Vidula , Morgan, Rebecca L.

Mayo Clinic

C39. PNEUMONIA AND SEPSIS: EPIDEMIOLOGY, TREATMENTS, AND OUTCOMES | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A5482-A5482

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a5482 Get It

Socioeconomic Deprivation Is Associated With Prevalence and Persistence of Airway Mucus Plugs in Patients With COPD
Mettler, S.K., Nath, P. H., Yen, A.A., Kligerman, Seth , Jacobs, Kathleen, Manapragada, Padma P. , Abozeed, Mostafa , Zahid, Mohd , Ahmed, Asmaa , Terry, Nina , Sonavane, Sushilkumar K. , Billatos, Ehab , Wang, Wei , Cho, M.H. , Grumley, Scott , Kim, Katherine Callaway , Nardelli, Pietro , Aziz, Muhammad Usman , Estépar, R. San José , Abdalla, Mazen A. , Díaz, Alejandro A.

Mayo Clinic

A54. EXPLORING ASTHMA AND COPD: DIVERSE INSIGHTS FROM GLOBAL PERSPECTIVES | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A2110-A2110

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a2110 Get It

Airway Mucus Plugging in Upper Versus Lower Lobes and Associations With Outcomes in COPD
Mettler, S.K., Nath, P. H., Yen, A.A., Kligerman, Seth , Jacobs, Kathleen, Manapragada, Padma P. , Abozeed, Mostafa , Zahid, Mohd , Ahmed, Asmaa , Terry, Nina , Elalami, Rim, Sonavane, Sushilkumar K. , Billatos, Ehab , Wang, Wei , Cho, M.H. , Grumley, Scott , Kim, Katherine Callaway , Nardelli, Pietro , Aziz, Muhammad Usman , Estépar, Raúl San Jośe , Abdalla, Mazen A. , Díaz, Alejandro A.

Mayo Clinic

A29. WHAT IS YOUR DAMAGE? IMAGING-BASED PHENOTYPES OF COPD | April 30, 2024 | Volume: No volume available | Issue: No issue available | Pages: A1247-A1247

10.1164/ajrccm-conference.2024.209.1_meetingabstracts.a1247 Get It